Stocks · News reference

Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy

Aug 10, 2026, 2:03 PMVandana Singh

Sobi and Innate Pharma partner for a Phase 3 trial of lacutamab targeting rare skin cancer, featuring a $75 million upfront payment.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 14, 2026, 12:06 PMBenzinga Insights
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Capricor Therapeutics (NASDAQ:CAPR) stock rose 94.8% to $8.2 during Friday's pre-market session. The company's market cap stands at $243.8 million. As per the news, the Q2 earnings report came out
Read original at benzinga
AKAN BYSI CAPR CBUS ETON
BenzingaAug 12, 2026, 3:09 PMBenzinga Newsdesk
Innate Pharma shares are trading higher after BTIG maintained its Buy rating on the stock and raised its price target from $8 to $9.
Read original at benzinga
IPHA
BenzingaAug 12, 2026, 9:29 AMBenzinga Newsdesk
BTIG Maintains Buy on Innate Pharma, Raises Price Target to $9
BTIG analyst Jeet Mukherjee maintains Innate Pharma (NASDAQ:IPHA) with a Buy and raises the price target from $8 to $9.
Read original at benzinga
IPHA
BenzingaAug 10, 2026, 6:04 PMBenzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Innate Pharma, Raises Price Target to $7
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Innate Pharma (NASDAQ:IPHA) with a Buy and raises the price target from $5 to $7.
Read original at benzinga
IPHA